KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
MORRISTOWN, N.J., Feb. 18, 2016 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference, as follows.
| Date: | Wednesday, February 24, 2016 |
| Time: | 1:35 PM EST |
| Location: | New York, NY - The New York Palace Hotel |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Matthew P. Duffy, 212.915.0685 LifeSci Advisors, LLC [email protected]
